TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) had its price target lowered by equities research analysts at HC Wainwright from $19.00 to $14.00 in a report released on Thursday, The Fly reports. HC Wainwright’s price target suggests a potential upside of 495.74% from the company’s current price.
Several other research analysts have also issued reports on the stock. The Goldman Sachs Group lowered shares of TCR2 Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $28.00 to $5.00 in a research note on Wednesday, January 19th. Piper Sandler decreased their price target on shares of TCR2 Therapeutics from $23.00 to $15.00 in a research note on Thursday, May 12th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.94.
Shares of NASDAQ TCRR opened at $2.35 on Thursday. TCR2 Therapeutics has a 12 month low of $2.10 and a 12 month high of $20.07. The firm has a market capitalization of $90.58 million, a PE ratio of -0.84 and a beta of 2.22. The firm has a fifty day simple moving average of $2.52 and a two-hundred day simple moving average of $3.74.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Macquarie Group Ltd. purchased a new position in shares of TCR2 Therapeutics in the third quarter worth approximately $30,000. BNP Paribas Arbitrage SA boosted its holdings in shares of TCR2 Therapeutics by 126.6% in the third quarter. BNP Paribas Arbitrage SA now owns 7,831 shares of the company’s stock worth $67,000 after buying an additional 4,375 shares during the last quarter. Point72 Hong Kong Ltd boosted its holdings in shares of TCR2 Therapeutics by 557.3% in the third quarter. Point72 Hong Kong Ltd now owns 11,023 shares of the company’s stock worth $94,000 after buying an additional 9,346 shares during the last quarter. Private Advisor Group LLC purchased a new position in shares of TCR2 Therapeutics in the fourth quarter worth approximately $52,000. Finally, Newman Dignan & Sheerar Inc. purchased a new position in shares of TCR2 Therapeutics in the first quarter worth approximately $30,000. 82.99% of the stock is currently owned by hedge funds and other institutional investors.
About TCR2 Therapeutics (Get Rating)
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
- Get a free copy of the StockNews.com research report on TCR2 Therapeutics (TCRR)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.